$1.420
+0.131 (+9.22%)Zum Schluss
ATNM-News
ATNM-Events
Actinium Pharmaceuticals Announces Initial Results of ATNM-400 Clinical Trial
Actinium Pharmaceuticals announced "encouraging" initial clinical results from the first-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant prostate cancer, or mCRPC. The findings, presented in an oral presentation on October 19 at the 39th Annual Congress of the European Association of Nuclear Medicine in Vienna,showed a favorable initial safety profile at the first dose level and tumor uptake and retention with the HER3-targeted imaging agent. Dose escalation has advanced to 1.5 microCi/kg and is ongoing. Preclinical findings support broad potential beyond Prostate-Specific Membrane Antigens, or PSMA. ATNM-400 demonstrated antitumor activity across PSMA-high, PSMA-low and PSMA-negative prostate cancer models, supporting its potential to address patients underserved by PSMA-directed therapies. HER3-directed imaging demonstrated tumor uptake and retention. Encouraging initial safety findings supported continued dose escalation.
Actinium Pharmaceuticals Presents ATNM-400 Data at Nuclear Medicine Congress
Actinium Pharmaceuticals announced three presentations, including an oral presentation and two e-posters, highlighting preclinical data supporting ATNM-400's broad potential at the 39th Annual Congress of the European Association of Nuclear Medicine, October 17-21, 2026, in Vienna, Austria. The presentations feature ATNM-400, the company's first-in-class Actinium-225 radiotherapy, in non-small cell lung cancer, colorectal cancer, and ovarian cancer models. Together, the studies demonstrate preclinical antitumor activity as monotherapy and enhanced activity in combination with standard-of-care agents, supporting both approaches to development across solid tumors. These findings further expand the preclinical evidence supporting ATNM-400's potential across multiple cancer indications, complementing its ongoing clinical development in metastatic castration-resistant prostate cancer. In NSCLC, ATNM-400 demonstrated antitumor activity as monotherapy and enhanced activity in combination with KRAS or ALK inhibitors, including in resistant models. These findings extend earlier EGFR-mutant results and support mutation-agnostic development both as a standalone therapy and in combination with established treatments. In colorectal cancer, ATNM-400 demonstrated monotherapy activity in SW620 xenografts and enhanced activity when combined with bevacizumab plus oxaliplatin in HCT15 xenografts, a model with moderate target expression and limited response to the standard-of-care combination. These findings support both monotherapy development and combinations aimed at improving outcomes in poorly responsive disease. In ovarian cancer, ATNM-400 monotherapy produced durable antitumor activity, including in bevacizumab-refractory tumors. These findings support its potential as a standalone treatment in recurrent disease, with further evaluation of ATNM-400 alone and in combination with standard-of-care therapies extending this development strategy.
Actinium Pharmaceuticals Appoints Matt David as CFO
Actinium Pharmaceuticals appointed Matt David as CFO. David joins Actinium from CorMedix, where he most recently served as EVP and Chief Business Officer. He joined CorMedix in 2020 as EVP and CFO. Prior to his roles at CorMedix, David served as Head of Strategy at Ovid Therapeutics. Before moving into industry, he spent more than a decade in healthcare investment banking, including at BofA Merrill Lynch, Thomas Weisel Partners and Piper Jaffray, and at Lehman Brothers.
Actinium Pharmaceuticals Presents New Data on ATNM-400 at Lung Cancer Conference
Actinium Pharmaceuticals on June 2 presented new preclinical data on ATNM-400 in non-small cell lung cancer, or NSCLC, at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting in Los Angeles, California. The new KRAS-mutant data, together with a growing body of EGFR-mutant data, demonstrate ATNM-400's activity across the two major mutation driver classes in NSCLC and support a distinct strategic opportunity. ATNM-400 can be developed as a potential mutation-agnostic backbone for the broader NSCLC market, alone or in combination with standard-of-care therapies, rather than as another mutation-specific drug for a narrow subset. NSCLC accounts for roughly 85% of the more than two million lung cancer cases diagnosed globally each year, a market more than twice the size of prostate cancer. It is also highly heterogeneous: no single mutation dominates, so treatments are fragmented across mutation-specific therapies such as EGFR, KRAS, BRAF, ALK and others, each marketed by different companies, each addressing only a molecular subset, and each ultimately limited by acquired resistance. ATNM-400, Actinium-225 antibody radioconjugate, is designed to break out of that single-mutation paradigm. Rather than blocking a specific mutant protein, it delivers a high-linear-energy-transfer alpha-particle payload that induces dense, irreversible double-strand DNA breaks and tumor-cell death independent of a tumor's driver mutation or signaling pathway, the mechanistic basis of its mutation-agnostic activity. In new KRAS-mutant studies presented at SNMMI, sotorasib and adagrasib increased ATNM-400's target up to 3.5- and 3.8-fold, respectively, and adding ATNM-400 deepened tumor-cell killing beyond either inhibitor alone. These results demonstrate the same target-expression increasing, synergy-enabling biology shown previously with the EGFR inhibitor osimertinib, which produced tumor growth inhibition of 107% when combined with ATNM-400. These combination benefits also broaden ATNM-400's commercial opportunity. The franchises it could enhance are substantial; the KRAS inhibitor class in NSCLC is projected to exceed $5B in peak sales, and the EGFR-mutant segment has peak sales estimates over $15B, led by osimertinib which generated $7.3B in 2025. This positions ATNM-400 to participate in these established markets by enhancing the standard of care, while also reaching the broader NSCLC population beyond any single mutation.
Actinium Appoints Steffen Heeger as Chief Medical Officer
Actinium Pharmaceuticals announced the appointment of Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination of radiotherapy expertise, global oncology drug development leadership, and public-company experience. Over his career, he has translated multiple programs from IND submission through global clinical approval in the US, EU, and Japan including the blockbuster Erbitux and led as CMO an oncology company acquired for $1.4B. Most recently Dr. Heeger served as CMO of a clinical-stage radiotherapy company where he advanced into global development, a PSMA program directly relevant to Actinium's ATNM-400 asset. His appointment comes at a pivotal moment as Actinium prepares to advance Actimab-A, ATNM-400, and Iomab-ACT toward key data readouts and expanded clinical trials in the second half of 2026.
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.